IVORC
  • Register
  • Login

Medical hypothesis discovery and innovation in ophthalmology

  1. Home
  2. Archives
  3. Vol. 9 No. 4 (2020): Winter 2020
  4. Articles

About the Journal

Editorial Team

Privacy Statement

Contact

Non-inferiority evaluation of preservative-free latanoprost/timolol eye drops solution versus preserved latanoprost/timolol eye drops in patients with high intraocular pressure and open-angle glaucoma

  • Panos Theodosiadis
  • Anastasios Konstas
  • Ioannis Halkiadakis
  • Vasiliki Dimera
  • Dimitrios Koufakis
  • Constantinos D Georgakopoulos
  • Evgenia Kanonidou
  • Elias Zintzaras
  • Michael Lygeros
  • Konstantina Soulele
  • Antonios Margaritis
  • Lida Kalantzi

Medical hypothesis discovery and innovation in ophthalmology, Vol. 9 No. 4 (2020), 28 February 2021 , Page 255-263
https://doi.org/10.51329/mehdiophthal1411 Published 28 February 2021

  • View Article
  • Download
  • Share

Abstract

Background: This study aimed to evaluate the non-inferiority and safety of a newly developed preservative-free (PF) multi-dose latanoprost/timolol ophthalmic solution, compared with the benzalkonium chloride (BAK)-preserved fixed combination, in patients with open-angle glaucoma and ocular hypertension.
Methods: A Phase III randomized multi-center observer-blind parallel-group clinical trial was conducted. A total of 210 adult patients (aged over 18 years) were randomly treated with the PF- or the BAK-preserved latanoprost/timolol solution once daily in the affected eye(s) for 12 weeks. Follow-up visits were scheduled at weeks 2, 6, and 12; intraocular pressure (IOP) was recorded at 8:00 AM, 12:00 PM, and 4:00 PM. The primary efficacy endpoint to prove non-inferiority was the IOP change at 8:00 AM (± 1 hour) from the baseline to the end of treatment (week 12) in the studied eye. Safety parameters were also assessed.
Results: In total, 196 patients completed the study. The pressure-lowering effect of the PF eye drops was comparable to that of the preserved formulation at all time points. Latanoprost/timolol PF formulation was non-inferior to the BAK-preserved solution as shown by the change in IOP from day 0 to week 12. The point estimate of the inter-treatment difference was 0.624 mmHg (95% CI: -0.094, 1.341). Both treatments were well-tolerated during the study, and they had similar adverse event profiles.
Conclusions: PF-latanoprost/timolol combination was found to be non-inferior to the BAK-preserved formulation based on the efficacy at all times, with similar local tolerance.
  • Full Text PDF
  • Abstract Viewed: 285 times
  • Full Text PDF Downloaded: 204 times

Download Statastics

  • Linkedin
  • Twitter
  • Facebook
  • Google Plus
  • Telegram
Open Journal Systems
Current Issue
  • Atom logo
  • RSS2 logo
  • RSS1 logo
Information
  • For Readers
  • For Authors
  • For Librarians
  • Home
  • Archives
  • Submissions
  • About the Journal
  • Editorial Team
  • Contact

ISSN: 2322-3219

This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0).
© Copyright 2012-2023, CC BY-NC 4.0. All Rights Reserved.